OncoMatch/Clinical Trials/NCT05170399
Vaccine Responses in Patients With B Cell Malignancies
Is NCT05170399 recruiting? Yes, currently enrolling (May 2026). This Phase 4 trial studies multiple treatments for lymphoma.
Treatment: Fluzone · Shingrix · Flucelvax · Afluria · PREVNAR 13 · Heplisav -B · Pfizer-COVID-19 Vaccine · FluLaval · Fluarix · PNEUMOVAX 23 · PREVNAR 20 · AREXVY, ABRYSVO — Background: People with B cell malignancies (blood cancers) often cannot mount a full immune response to infections or certain vaccines. Bruton tyrosine kinase inhibitors (BTKis), which are used to treat blood cancers, may also negatively affect a person s response to certain vaccines. Researchers want to learn more about vaccine responses in people with certain types of blood cancers. The findings may help develop better vaccine strategies for people with these cancers. Objective: To learn how well vaccines work in people who have certain types of blood cancers. Eligibility: Adults aged 18 years or older who have chronic lymphocytic leukemia (CLL), Waldenstrom macroglobulinemia, or certain non-Hodgkin lymphomas. Design: Participants will get one or more vaccines for illnesses such as COVID-19, hepatitis B, and shingles. They can choose which vaccines they receive. They will give a blood sample before they get each vaccine. Some vaccines require a second dose 3-6 weeks later. Participants may give an optional blood sample with the second vaccine dose. About 4 weeks after they finish each vaccine series, they will give another blood sample. They will have 2-3 study visits per vaccine. Participants may receive a booster dose for some vaccines. The booster dose is optional. They will give another blood sample with the booster dose. Participants will have pregnancy tests, if needed. Participants with CLL who receive BTKis may be asked to pause treatment for up to 7 weeks. Participants may give follow-up blood samples up to 2 times a year for 5 years. These blood samples are optional. Participation will last for up to 5 years after each vaccine series is received.
Check if I qualifyExtracted eligibility criteria
Cancer type
Non-Hodgkin Lymphoma
Prior therapy
Cannot have received: cytotoxic chemotherapy
Receive cytotoxic chemotherapy within 2 weeks prior to vaccination
Cannot have received: intravenous immunoglobulin (IVIG)
Receive intravenous immunoglobulin (IVIG) within 2 months prior to vaccination
Cannot have received: anti-CD20 monoclonal antibody
Receive anti-CD20 and/or anti-CD19 monoclonal antibody therapy within 6 months prior to vaccination
Cannot have received: anti-CD19 monoclonal antibody
Receive anti-CD20 and/or anti-CD19 monoclonal antibody therapy within 6 months prior to vaccination
Cannot have received: cellular therapy (CAR-T cells)
Receive cellular therapy (e.g. CAR-T cells) within 12 months prior to vaccination
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- National Institutes of Health Clinical Center · Bethesda, Maryland
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify